Long-term tumor control after brachytherapy for base-of-prostate cancer

Autor: Seungtaek Choi, Teresa L. Bruno, Quynh-nhu Nguyen, Andrew K. Lee, Deborah A. Kuban, Thomas J. Pugh, David A. Swanson, Rajat J. Kudchadker, Jason M. Samuelian, Steven J. Frank
Jazyk: angličtina
Rok vydání: 2011
Předmět:
Zdroj: Journal of Contemporary Brachytherapy, Vol 3, Iss 4, Pp 183-187 (2011)
Druh dokumentu: article
ISSN: 1689-832X
2081-2841
Popis: Purpose: To evaluate the outcomes of patients presenting with cancer at the base of the prostate after brachytherapyas monotherapy. Material and methods: We retrospectively reviewed the medical records of all patients who had undergone transpe -ri neal ultrasound-guided implantation with 125I or 103Pd seeds as monotherapy between March 1998 and December2006, at our institution. A minimum follow-up interval of 2 years was required for inclusion in our analysis. Dosimetrywas assessed using computed tomography 30 days after the implant. Treatment failure was defined as the appearanceof biopsy-proved tumor after seed implantation, radiographic evidence of metastases, receipt of salvage therapy,or elevation of the prostate-specific antigen level beyond the nadir value plus 2 ng/mL. Results: With a median follow-up interval of 89 months (range 25-128 months), all 52 of the identified patients hadno evidence of disease progression or biochemical failure. The mean number of cores sampled at the prostate base was2.84 (median 2); Gleason scores assigned at central review were 6-8 in all patients. Of the 30 patients (58%) for whomdosimetric data were available at day 30, the median V100 values of the right and left base were 92.0% and 93.5%, respectively,and the median D90 values of the right and left base were 148 Gy and 151 Gy, respectively. Conclusion: Permanent prostate brachytherapy as monotherapy results in a high probability of disease-free survivalfor men with cancer at the base of the prostate.
Databáze: Directory of Open Access Journals
Externí odkaz: